‘Skinny Label’ Case Gives Brands A ‘Blueprint’ To Alter Use Codes In Patent Litigation

Implications Of GSK v. Teva 'Scarier For Biosimilars'

 
• By Brenda Sandburg
  
carve-out
Label-carve out case raises concerns about biosimilar litigation and marketing • Source: Alamy

More from Legal & IP

More from Generics Bulletin